SCHEMBL770894

SCHEMBL770894

CN1CCN(C(=O)CC(=O)N2CCC3CCCC=C3C2)CC1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 3/20 0.39
MAOB P27338 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.36
HTT P42858 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
L3MBTL3 Q96JM7 1/20 0.35
TDP1 Q9NUW8 1/20 0.34
MAPT P10636 1/20 0.34
ALDH1A1 P00352 2/20 0.34
LMNA P02545 1/20 0.34
RAD52 P43351 1/20 0.34
CACNA2D1 P54289 1/20 0.34
CACNA1B Q00975 1/20 0.34
CACNB1 Q02641 1/20 0.34
CACNA1C Q13936 1/20 0.34
NAMPT P43490 1/20 0.34
MCHR1 Q99705 1/20 0.34
KMT2A Q03164 1/20 0.33
RBP4 P02753 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770448 0.92 SMN1; SMN2 (0.44) KDM1AMAOBSMN1; SMN2HTTL3MBTL1
SCHEMBL771078 0.90 NPC1 (0.42) KDM1AMAOBSMN1; SMN2HTTMAPT
SCHEMBL770075 0.88 ALDH1A1 (0.42) SMN1; SMN2L3MBTL1ALDH1A1LMNAKMT2A
SCHEMBL770397 0.88 ALDH1A1 (0.36) SMN1; SMN2HTTL3MBTL3TDP1MAPT
SCHEMBL771570 0.85 L3MBTL3 (0.37) SMN1; SMN2HTTL3MBTL1L3MBTL3TDP1
SCHEMBL770666 0.84 RBP4 (0.44) SMN1; SMN2TDP1MAPTALDH1A1RBP4
SCHEMBL770303 0.83 PDE4B (0.47) ALDH1A1LMNAKMT2A
SCHEMBL770293 0.82 KMT2A (0.37) ALDH1A1LMNAKMT2A
SCHEMBL771656 0.82 MAPK1 (0.36) SMN1; SMN2HTTMAPTALDH1A1LMNA
SCHEMBL770187 0.82 TSHR (0.49) HTTMAPTALDH1A1KMT2ARBP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 KDM1A 2065/4885MAOB 1576/4885SMN1; SMN2 3653/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 KDM1A 2083/4885MAOB 1581/4885SMN1; SMN2 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.